Download PDF
Thromb Haemost 1995; 73(05): 739-742
DOI: 10.1055/s-0038-1653860
Rapid Communication
Schattauer GmbH Stuttgart

Resistance to Activated Protein C, the Arg506 to Gin Mutation in the Factor V Gene, and Venous Thrombosis

Functional Tests and DNA-based Assays, Pros and Cons
Björn Dahlbäck
The Department of Clinical Chemistry, Lund University, Malmö General Hospital, Malmö, Sweden
› Author Affiliations
Further Information

Publication History

Received 18 January 1995

Accepted after resubmission 03 March 1995

Publication Date:
09 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Goldhaber SZ. Epidemiology of pulmonary embolism and deep vein thrombosis. In: Haemostasis and Thrombosis 3 rd ed. Bloom AL, Forbes CD, Thomas DP, Tuddenhamm EG D. (eds) Churchill Livingstone; 1994. pp 1327-1333
    Google Scholar
  • 2 Allaart CF, Briët E. Familial venous thrombophilia. In: Haemostasis and Thrombosis 3rd ed. Bloom AL, Forbes CD, Thomas DP, Tuddenham EG D. (eds) Churchill Livingstone; 1994. pp 1349-1360
    Google Scholar
  • 3 Malm J, Laurell M, Nilsson IM, Dahlbäck B. Thromboembolic disease - critical evaluation of laboratory investigation. Thromb Haemost 1992; 68: 7-13
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Heijboer H, Brandjes D, Büller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep- vein thrombosis. N Engl J Med 1990; 323: 1512-1516
    CrossrefPubMedGoogle Scholar
  • 5 Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited pre- disposion to thrombosis. Cell 1993; 72: 477-480
    CrossrefPubMedGoogle Scholar
  • 6 Tabemero MD, Tomas JF, Alberca I, Orfao A, Borrasca AL, Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 1991; 36: 249-254
    CrossrefPubMedGoogle Scholar
  • 7 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
    CrossrefPubMedGoogle Scholar
  • 8 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-521
    CrossrefPubMedGoogle Scholar
  • 9 Koster T, Rosendaal FR, de Ronde F, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor response to activated protein C: Ixiden thrombophilia study. Lancet 1993; 342: 1503-1506
    CrossrefPubMedGoogle Scholar
  • 10 Halbmayer WM, Haushofer A, Schön R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinol 1994; 5: 51-57
    CrossrefPubMedGoogle Scholar
  • 11 Cadroy Y, Siè P, Boneu B. Frequency of a defective response to activated protein C in patients with a history of venous thrombosis. Blood 1994; 83: 2008-2009
    PubMedGoogle Scholar
  • 12 Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in a majority of thrombophilie patients. Blood 1993; 82: 1989-1993
    PubMedGoogle Scholar
  • 13 Bertina RM, Koeleman BP C, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
    CrossrefPubMedGoogle Scholar
  • 14 Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506GIn mutation in factor V a. Lancet 1994; 343: 1362-1363
    PubMedGoogle Scholar
  • 15 Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-1538
    CrossrefPubMedGoogle Scholar
  • 16 Voorberg J, Roelse J, Koopman R, Büller H, Berends F, ten Cate JW, Mertens K, van Mourik JA. Association of idiopathic thromboembolism with single point mutation at Arg506 of factor V. Lancet 1994; 343: 1535-1536
    CrossrefPubMedGoogle Scholar
  • 17 Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-2524
    CrossrefPubMedGoogle Scholar
  • 18 Majerus PW. Bad blood by mutation. Nature 1994; 369: 14-15
    CrossrefPubMedGoogle Scholar
  • 19 Sun X, Evatt B, Griffin JH. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood 1994; 83: 3120-3125
    PubMedGoogle Scholar
  • 20 Dahlbäck B. Physiological anticoagulation. Inherited resistance to activated protein C and venous thromboembolism J Clin Invest 1994; 94: 923-927
    CrossrefPubMedGoogle Scholar
  • 21 Beauchamp NJ, Daly ME, Hampton KK, Cooper PC, Preston E, Peake IR. High prevalence of a mutation in the factor V gene within the UK population: Relationship to activated protein C resistance and familial thrombosis. Br J Haematol 1994; 88: 219-222
    CrossrefPubMedGoogle Scholar
  • 22 Koeleman BP C, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-1035
    PubMedGoogle Scholar
  • 23 Zöller B, Bemtsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood. 1995
    PubMedGoogle Scholar
  • 24 Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457
    CrossrefPubMedGoogle Scholar
  • 25 Hellgren M, Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 1995
    PubMedGoogle Scholar
  • 26 Miletich JP, Sherman L, Broze Jr GJ. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991-996
    CrossrefPubMedGoogle Scholar
  • 27 Zöller B, He X, Dahlback B. Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease. Thromb Haemost. 1995
    PubMedGoogle Scholar
  • 28 Dahlbäck B. Inherited thrombophilia: Resistance to activated protein C as a pathogenic factor of venous thrombosis. Blood 1995; 85: 607-614
    PubMedGoogle Scholar
  • 29 Rosén S, Johansson K, Lindberg K, Dahlbäck B. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. Thromb Haemost 1994; 72: 255-260
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-886
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Trossaërt M, Conard J, Horellou MH, Samama MM. Influence of storage conditions on activated protein C resistance assay. Thromb Haemost 1995; 73: 163-164
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Faioni EM, Franchi F, Asti D, Sacchi E, Bemardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilie families: Interference in a protein S functional assay. Thromb Haemost 1993; 70: 1067-1071
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. Biochemistry 1992; 31: 3777-3785
    CrossrefPubMedGoogle Scholar